Literature DB >> 22214661

Deconvoluting mTOR biology.

Jason D Weber1, David H Gutmann.   

Abstract

In metazoans, TOR is an essential protein that functions as a master regulator of cellular growth and proliferation. Over the past decade, there has been an explosion of information about this critical master kinase, ranging from the composition of the TOR protein complex to its ability to act as an integrator of numerous extracellular signals. Unfortunately, this plethora of information has also raised numerous questions regarding TOR function. Currently, the prevailing view is that mammalian TOR (mTOR) exists in at least two molecular complexes, mTORC1 and mTORC2, which are largely defined by the presence of either RAPTOR or RICTOR. However, additional co-factors have been identified for each complex, and their importance in mediating mTOR signals has been incompletely elucidated. Similarly, there are differences in mTOR function that reflect the tissue of origin. In this review, we present an alternative view to mTOR complex formation and function, which envisions mTOR regulation and signal propagation as a reflection of cell type- and basal state-dependent conditions. The re-interpretation of mTOR biology in this framework may facilitate the design of therapies most likely to effectively inhibit this central regulator of cell behavior.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22214661      PMCID: PMC3293376          DOI: 10.4161/cc.11.2.19022

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  146 in total

Review 1.  mTOR Signalling in Health and Disease.

Authors:  Christopher G Proud
Journal:  Biochem Soc Trans       Date:  2011-04       Impact factor: 5.407

Review 2.  mTOR complex 2 signaling and functions.

Authors:  Won Jun Oh; Estela Jacinto
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

3.  Protor-1 is required for efficient mTORC2-mediated activation of SGK1 in the kidney.

Authors:  Laura R Pearce; Eeva M Sommer; Kei Sakamoto; Stephan Wullschleger; Dario R Alessi
Journal:  Biochem J       Date:  2011-05-15       Impact factor: 3.857

4.  Activation of mTORC2 by association with the ribosome.

Authors:  Vittoria Zinzalla; Daniele Stracka; Wolfgang Oppliger; Michael N Hall
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 5.  mTOR: from growth signal integration to cancer, diabetes and ageing.

Authors:  Roberto Zoncu; Alejo Efeyan; David M Sabatini
Journal:  Nat Rev Mol Cell Biol       Date:  2010-12-15       Impact factor: 94.444

Review 6.  Tuberous sclerosis complex: neurological, renal and pulmonary manifestations.

Authors:  D N Franz; J J Bissler; F X McCormack
Journal:  Neuropediatrics       Date:  2011-01-05       Impact factor: 1.947

7.  mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways.

Authors:  Pat Gulhati; Kanika A Bowen; Jianyu Liu; Payton D Stevens; Piotr G Rychahou; Min Chen; Eun Y Lee; Heidi L Weiss; Kathleen L O'Connor; Tianyan Gao; B Mark Evers
Journal:  Cancer Res       Date:  2011-03-23       Impact factor: 12.701

8.  Identification of FUSE-binding protein 1 as a regulatory mRNA-binding protein that represses nucleophosmin translation.

Authors:  M E Olanich; B L Moss; D Piwnica-Worms; R R Townsend; J D Weber
Journal:  Oncogene       Date:  2010-08-30       Impact factor: 9.867

9.  Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size.

Authors:  Abdelhafid Saci; Lewis C Cantley; Christopher L Carpenter
Journal:  Mol Cell       Date:  2011-04-08       Impact factor: 17.970

Review 10.  Mammalian target of rapamycin: hitting the bull's-eye for neurological disorders.

Authors:  Zhao Zhong Chong; Yan Chen Shang; Lijie Zhang; Shaohui Wang; Kenneth Maiese
Journal:  Oxid Med Cell Longev       Date:  2010-11-01       Impact factor: 6.543

View more
  41 in total

Review 1.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

2.  Mechanistic target of rapamycin (mTOR) implicated in plasticity of the reproductive axis during social status transitions.

Authors:  Karen P Maruska; Young Chang Sohn; Russell D Fernald
Journal:  Gen Comp Endocrinol       Date:  2019-06-18       Impact factor: 2.822

Review 3.  Receptor tyrosine kinase (RTK) signalling in the control of neural stem and progenitor cell (NSPC) development.

Authors:  Alexander Annenkov
Journal:  Mol Neurobiol       Date:  2013-08-28       Impact factor: 5.590

4.  Actin up in the Nucleus: Regulation of Actin Structures Modulates Mesenchymal Stem Cell Differentiation.

Authors:  Janet Rubin; Buer Sen
Journal:  Trans Am Clin Climatol Assoc       Date:  2017

Review 5.  mTOR inhibition in epilepsy: rationale and clinical perspectives.

Authors:  Adam P Ostendorf; Michael Wong
Journal:  CNS Drugs       Date:  2015-02       Impact factor: 5.749

Review 6.  Application and interpretation of current autophagy inhibitors and activators.

Authors:  Ya-ping Yang; Li-fang Hu; Hui-fen Zheng; Cheng-jie Mao; Wei-dong Hu; Kang-ping Xiong; Fen Wang; Chun-feng Liu
Journal:  Acta Pharmacol Sin       Date:  2013-03-25       Impact factor: 6.150

7.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study.

Authors:  Brian Weiss; Brigitte C Widemann; Pamela Wolters; Eva Dombi; Alexander Vinks; Alan Cantor; John Perentesis; Elizabeth Schorry; Nicole Ullrich; David H Gutmann; James Tonsgard; David Viskochil; Bruce Korf; Roger J Packer; Michael J Fisher
Journal:  Neuro Oncol       Date:  2014-10-14       Impact factor: 12.300

8.  mTOR as a potential treatment target for epilepsy.

Authors:  Michael Wong
Journal:  Future Neurol       Date:  2012-09-01

Review 9.  Optimizing biologically targeted clinical trials for neurofibromatosis.

Authors:  David H Gutmann; Jaishri O Blakeley; Bruce R Korf; Roger J Packer
Journal:  Expert Opin Investig Drugs       Date:  2013-02-21       Impact factor: 6.206

10.  A unique herpesviral transcriptional program in KSHV-infected lymphatic endothelial cells leads to mTORC1 activation and rapamycin sensitivity.

Authors:  Henry H Chang; Don Ganem
Journal:  Cell Host Microbe       Date:  2013-04-17       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.